Renal impairment associated with myeloproliferative neoplasms

Abstract

Myeloproliferative neoplasms (MPNs), which include polycythemia vera, essential thrombocythemia, and primary myelofibrosis (PMF), have been identified as having a notable association with renal impairment. Among these, MPN-related glomerulopathy has garnered particular attention due to its prevalence in patients with PMF. Chronic kidney disease has a significant impact on the general population and is also associated with a substantial risk of thrombosis and poorer overall survival in MPN patients. Emerging evidence suggests that treatments such as cytoreductive therapy and ruxolitinib may help improve renal function in these patients. Given the significant implications of renal impairment on prognosis and disease outcomes, thorough renal function assessment is essential in the clinical management of MPNs. Collaboration with nephrologists is strongly recommended to ensure comprehensive care, particularly in patients with confirmed or suspected renal complications.